NCT03370913: A reported trial by BioMarin Pharmaceutical
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03370913 |
|---|---|
| Title | A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients With Residual FVIII Levels ≤ 1 IU/dL Receiving Prophylactic FVIII Infusions |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 19, 2017 |
| Completion date | Nov. 16, 2020 |
| Required reporting date | Nov. 16, 2023, midnight |
| Actual reporting date | July 17, 2023 |
| Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
| Days late | None |